Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern
• By Penelope MacRae
Regulatory compliance issues at several of its facilities detracted from Lupin's strong financial performance in its fiscal first quarter • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
